Loading...
•
Dec 31, 2019
Avantor Q4 2019 Earnings Report
Reported financial results for the quarter and year ended December 31, 2019.
Key Takeaways
Avantor's Q4 2019 results showed strong sales, particularly in the biopharma business, margin expansion, and robust cash flow generation. Net sales increased by 3.4% to $1.52 billion, net income increased to $70.6 million, and adjusted EPS increased 89.9% to $0.19.
Net sales reached $1.52 billion with 3.4% increase.
Net income increased to $70.6 million.
Adjusted EBITDA increased 11.8% to $263.6 million.
Adjusted EPS increased 89.9% to $0.19.
Avantor
Avantor
Forward Guidance
The Company projects organic sales to be up 4% to 6% for 2020. Adjusted EBITDA is projected to be in the range of $1.090-1.135 billion, or an increase of 6% to 10%. Guidance for full-year adjusted EPS is $0.74-0.79, up 27-36%. Free cash flow is expected to be in the range of $450-500 million, up 50-65% from 2019.
Positive Outlook
- Organic sales to be up 4% to 6% for 2020
- Adjusted EBITDA is projected to be in the range of $1.090-1.135 billion, or an increase of 6% to 10%
- Full-year adjusted EPS is $0.74-0.79, up 27-36%
- Free cash flow is expected to be in the range of $450-500 million, up 50-65% from 2019.
- Current foreign exchange rates (e.g., Euro 1.11)
Challenges Ahead
- The timing and cost of future restructuring activities
- Charges related to the early retirement of debt
- Changes in tax rates
- Other non-recurring items.
- Factors described in “Risk Factors” in our Registration Statement on Form S-1 (File No. 333-229578) and our Form 10-K